All In Biotech

Drug Trial Radar · NCT05349383

Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities

Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities Using International Pharmacovigilance Database

Last checked: Nov 19, 2026Latest source record: Jun 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24,618

Actual

Start

Apr 22, 2022

Primary completion

May 22, 2022

Study completion Jun 1, 2022

Sponsor

Lead sponsor
Central South UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 27, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Although antibody-drug conjugate(ADC) has proved effective in treating many cancers, few patients receiving ADC may experience rare but life-threatening sepsis-related toxicities such as sepsis and septic shock. Today, data about sepsis/septic shock are scarce. The objective was to investigate reports of sepsis/septic shock adverse events related to ADC, including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin using international pharmacovigilance databases such as the FDA Adverse Event Reporting System (FAERS).

Conditions

  • Sepsis (SMQ)
  • Opportunistic Infections
  • Agranulocytosis

Interventions

  • Antibody-Drug ConjugateDrug

    Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies. ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin.

  • Antineoplastic and immunomodulating agents other than Antibody-Drug ConjugateDrug

    We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sepsis-related toxicity of antibody-drug conjugate.Time frame: Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.